no$gba android apk

no$gba android apk

Trump's tariff plans may 'derail' US inflation progress: YellenKeurig Dr Pepper Declares Quarterly Dividend

Samantha Steele, the Cook County Board of Review commissioner arrested last month for driving under the influence of alcohol after a car crash, won back her right to drive on a technicality after her first court appearance Friday. A first term commissioner on the three-member panel that hears property tax appeals, Steele crashed what she said was a friend’s car in Chicago’s Uptown neighborhood the night of Nov. 10. The incident made waves not only because she told responding officers at the scene that she was an elected official and often refused to cooperate with their orders, but also made crude comments to one of her arresting officers. Steele has not commented on the incident and virtually attended the Board of Review’s public meeting earlier this month. She did not speak to reporters after Friday’s proceedings. Those arrested for DUI typically have their license suspended, but Steele’s attorney, John Fotopoulos, petitioned for her driving privileges to be restored last month and won them back Friday after arguing the officer didn’t give her proper warning of the consequences of refusing a breathalyzer test. Fotopoulos said it might be more difficult for a police officer to properly fill out DUI paperwork than Police Department paperwork in a murder case. After hours of back and forth between Steele’s attorney and the prosecutor, as well as testimony from the arresting officer, Judge Athena James Frentzas granted Fotopuolos’ petition and set Feb. 14 as the date for Steele’s next appearance. Steele did take a brief field sobriety test during the November incident but wasn’t breathalyzed. According to the arrest report, “her eyes were bloodshot and glassy,” she smelled like alcohol, and appeared “to be swaying” during the field sobriety test. Body camera footage from the night of the crash showed officers taking an open but corked bottle of wine out of the passenger seat footwell. She admitted at the scene that she hit two other cars. Steele was later taken to the hospital after she said she’d hit her head during the crash. While there, according to the arrest report, she refused a breathalyzer test and repeatedly asked the police officer with her at the hospital “Is your penis that small?” Danny Yu, the officer who arrested Steele and was questioned about his penis size, said in court Friday that at the hospital he read Steele the warning that if a first time offender refuses or fails to complete all chemical sobriety tests requested, they could see their license suspended for a year. Yu, a seven-year veteran of the Chicago Police Department, said he’d made around a dozen DUI arrests before and that he interpreted Steele’s crude comments as part of her refusal. Prior to granting Steele her license back, the judge said Yu never specified what time Steele refused testing at the hospital. In paperwork from the night of the arrest, Yu wrote that Steele refused chemical sobriety testing at 9:15 p.m. In testimony on Friday, Yu said that the testing he was referring to was field sobriety testing that had been done before Steele was taken to the hospital. While one Republican member of the Cook County Board called for her resignation over how she treated officers at the scene — the crude statements received some national media attention — Democratic colleagues have declined to comment or called for “grace.” Steele also serves on the Lake County Indiana Property Tax Board of Appeals.

Donald Trump asked the Supreme Court to pause a law that would ban TikTok. The president-elect filed a brief urging SCOTUS to give him time to pursue a political resolution. Congress passed a law that requires TikTok's Chinese owners to divest or be banned from US app stores. President-elect Donald Trump asked the Supreme Court to pause the law that would ban TikTok in mid-January until after his inauguration. Trump filed a brief on Friday urging the top court to give him time to "pursue a political resolution" before agreeing to ban the social media app. In April, Congress passed a bipartisan law that established a nine-month deadline for TikTok's Chinese parent company to divest from the app or be barred from US app stores. Neither TikTok nor Trump's lawyers immediately responded to Business Insider's request for comment. BI also reached out to the Supreme Court. In the Friday filing, Trump's lawyers highlighted the president-elect's "consummate deal-making expertise," suggesting Trump has the "political will" to negotiate a resolution that would simultaneously "save the platform" and address the national security concerns highlighted in the Congressional bill. The nine-month deadline is officially up on January 19, which is one day before Trump assumes office for a second time. Trump previously supported a TikTok ban but appeared to change his mind in recent months. He met with the app's CEO earlier this month and said he had a "warm spot" in his heart for TikTok. Legal experts previously told BI that Trump has a couple of options to try to keep the app running in the US, including asking his Department of Justice to ignore the divest law or trying to rework strategic interpretations of the law. Trump and his lawyers also argue that the president-elect has a mandate from American voters to protect their free-speech rights, including those who use TikTok. "Moreover, President Trump is one of the most powerful, prolific, and influential users of social media in history," the file said." "Consistent with his commanding presence in this area, President Trump currently has 14.7 million followers on TikTok with whom he actively communicates, allowing him to evaluate TikTok's importance as a unique medium for freedom of expression, including core political speech," lawyers added.

NoneStitch Fix: Fiscal Q1 Earnings Snapshot

ARLINGTON, Texas — Micah Parsons rocked back and forth on the bench in agony after Cincinnati’s winning touchdown that followed a botched blocked punt from his Dallas Cowboys. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

High school boys basketball: Falcons edge East in Moir consolation bracketInterim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox Study stopped enrolling patients in all study arms Results affirm tecovirimat's strong safety profile Efficacy in patients with more severe disease not assessed in study NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced results from an interim analysis of the Study of Tecovirimat for Human Mpox Virus (STOMP) clinical trial (NCT05534984). NIAID reported that SIGA's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade II mpox. Based on this and additional analyses, the study Data Safety and Monitoring Board (DSMB) recommended to stop enrolling patients in the randomized arms of the study. NIAID accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients. Data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints. "Antivirals are most effective when administered early in the course of an infection and tend to demonstrate the greatest benefit in patients with more severe disease. The STOMP results are not unexpected as the study design was similar to the PALM007 study except it was in patients with mild to moderate clade II mpox compared to patients with clade I mpox. It is important to note that approximately 75% of mpox patients in the randomized arms of the STOMP trial received tecovirimat more than five days after symptom onset, and higher risk patients were included in an open-label arm," stated Diem Nguyen, Chief Executive Officer. Tecovirimat, also known as TPOXX, was developed in partnership with the U.S. Government and approved by the U.S. Food and Drug Administration to treat smallpox—a virus closely related to, but far more serious than, mpox. TPOXX was approved in 2018 based on data from 12 clinical trials of oral TPOXX in 700 healthy human volunteers, which showed no drug-related serious adverse events. Four pivotal trials in non-human primates (NHPs) and two pivotal trials in rabbits demonstrated that TPOXX significantly reduced both mortality and viral load in NHP infected with mpox virus and in rabbits infected with rabbitpox virus. The results of the animal efficacy studies were published in the July 5, 2018 issue of the New England Journal of Medicine . "Tecovirimat's mechanism of action is driven by halting viral transmission. Once virus is present in the system, the body's natural immune system plays a central role in clearing it, typically within two to four weeks in immune competent patients. Research results thus far indicate that early treatment with tecovirimat including post-exposure prophylaxis and treatment in severe cases may offer the greatest potential for patient benefit," stated Dennis Hruby, Chief Scientific Officer. Additionally, in this study, tecovirimat exhibited a safety profile comparable to placebo. These safety results are consistent with prior studies and further support the strong safety profile that has been observed with tecovirimat over the past 15 years. Dr. Nguyen continued, "We thank our partners, the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH), the patients who participated in this trial, and the investigators who supported this trial. Their unwavering dedication to public health has been instrumental in advancing our understanding of mpox and tecovirimat." Three randomized clinical trials, UNITY (Switzerland, Brazil, Argentina), Platinum-CAN (Canada), and EPOXI (EU), are enrolling mpox patients. Given the STOMP and PALM007 results and the design similarities across these mpox trials, the Company believes these ongoing trials are likely to yield similar results. About the STOMP Clinical Trial in Mpox The STOMP study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive mpox disease. Beginning in September 2022, the study enrolled participants with mpox from Argentina, Brazil, Japan, Mexico, Peru, Thailand, and the United States, including Puerto Rico, who had symptoms for less than 14 days. Participants were randomly (2:1) assigned to receive tecovirimat or a placebo for 14 days. The number of capsules and frequency of dosage were based on patient weight. Participants with severe disease, certain skin conditions, or significantly suppressed immune systems received open-label tecovirimat rather than being randomized. The study monitored participants' safety across randomized and open label arms. In the randomized arms, STOMP examined the time to full mpox lesion resolution, viral clearance, and study participants' reports of pain. Participants were followed for 28 days with a study site visit at day 29 and then again at day 57 for possible recrudescence of infection. About SIGA SIGA Technologies (SIGA) SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe and the UK for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com . Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the efficacy of tecovirimat to treat mpox in certain patient populations and the results of ongoing mpox clinical studies. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. The words "may," "continue," "estimate," "intend," "plan," "will," "believe," "project," "expect," "seek," "anticipate," "could," "should," "target," "goal," "potential" and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA's actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA's control, including, but not limited to, (i) the risk that BARDA elects, in its sole discretion as permitted under the 75A50118C00019 BARDA Contract (the "BARDA Contract"), not to exercise the remaining unexercised option under the BARDA Contract, (ii) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (iii) the risk that the BARDA Contract or U.S. Department of Defense contracts are modified or canceled at the request or requirement of, or SIGA is not able to enter into new contracts to supply TPOXX to, the U.S. Government, (iv) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX internationally, (v) the risk that potential products, including potential alternative uses or formulations of TPOXX that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (vi) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vii) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (viii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (ix) the risk that any challenge to SIGA's patent and other property rights, if adversely determined, could affect SIGA's business and, even if determined favorably, could be costly, (x) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (xi) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts to develop or market its products, (xii) the risk that changes in domestic or foreign economic and market conditions may affect SIGA's ability to advance its research or may affect its products adversely, (xiii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA's businesses, (xiv) the risk of disruptions to SIGA's supply chain for the manufacture of TPOXX®, causing delays in SIGA's research and development activities, causing delays or the re-allocation of funding in connection with SIGA's government contracts, or diverting the attention of government staff overseeing SIGA's government contracts, (xv) risks associated with actions or uncertainties surrounding the debt ceiling, (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA's business, and (xvii) risks associated with responding to an mpox outbreak, as well as the risks and uncertainties included in Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2023 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov . All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Contacts: Suzanne Harnett sharnett@siga.com and Investors Media Jennifer Drew-Bear, Edison Group Holly Stevens, Berry & Company Jdrew-bear@edisongroup.com hstevens@berrypr.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Is Nvidia a Good Buy? Think Twice Before You Decide

Share this Story : Feds ignored calls to rename Victims of Communism memorial Copy Link Email X Reddit Pinterest LinkedIn Tumblr Breadcrumb Trail Links Defence Watch Feds ignored calls to rename Victims of Communism memorial A report commissioned by the Department of Canadian Heritage suggested renaming the monument, which opens on Dec. 12. Get the latest from David Pugliese, Ottawa Citizen straight to your inbox Sign Up Author of the article: David Pugliese • Ottawa Citizen Published Dec 10, 2024 • 4 minute read Join the conversation You can save this article by registering for free here . Or sign-in if you have an account. Victims of Communism Monument in Ottawa. The monument is expected to open Dec. 12. Photo by Tony Caldwell / Postmedia Article content The federal government was told it should change the name of the controversial Victims of Communism memorial to better reflect the experience of others who found refuge in Canada. Article content Article content The recommendation, made last year by a historian, was to change the name to “Memorial to the Victims of Communism and other authoritarian regimes-Canada a Land of Refuge,” according to government documents obtained by the Ottawa Citizen. Advertisement 2 Story continues below This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles from Elizabeth Payne, David Pugliese, Andrew Duffy, Bruce Deachman and others. Plus, food reviews and event listings in the weekly newsletter, Ottawa, Out of Office. Unlimited online access to Ottawa Citizen and 15 news sites with one account. Ottawa Citizen ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Sign In or Create an Account Email Address Continue or View more offers If you are a Home delivery print subscriber, online access is included in your subscription. Activate your Online Access Now Article content Government officials, however, decided not to follow the recommendation even though they were told it was consistent with conclusions reached separately and earlier by the National Capital Commission. The “Memorial to the Victims of Communism-Canada a Land of Refuge” will officially open Dec. 12. The unveiling of the memorial was put on hold last year because of the controversy over parliamentarians honouring a Waffen SS soldier and potential links between the monument and Nazi collaborators, according to records obtained by the Ottawa Citizen. In addition, Jewish groups have voiced their ongoing concerns about the names of alleged Nazi collaborators and other fascists being inscribed on the memorial. The memorial, located near the corner of Wellington and Bay streets, is supposed to honour those who suffered under communism. But last year the Department of Canadian Heritage commissioned a report from University of Ottawa historian Roman Krakovsky to examine various issues and problems with the initiative. The initial recommendation was to change the memorial’s name. Advertisement 3 Story continues below This advertisement has not loaded yet, but your article continues below. Article content “This recommendation is consistent with the extensive experience of Canada as a land of refuge for individuals and groups fleeing authoritarian regimes worldwide,” Krakovsky pointed out. That name change would also honour those who fled from Uganda in 1972, Kosovo in 1999, various locations in Asia, and from the military dictators who took over Chile in 1973. “As a monument of national historical significance, the experience the Memorial commemorates must go beyond the experience of a special group of individuals, in this case, those who fled Communism,” Krakovsky noted. But in the final report accepted by Canada Heritage the name change was removed. Department official Patryk Polec wrote to Krakovsky that his recommendation was “not required.” Krakovsky said in an interview on Dec. 10 that changing the name of the monument would have “been more generous and allowed for experiences of all refugees, all groups who found a home in Canada” and escaped from totalitarian regimes. “Why they (Canadian Heritage) refused, I don’t know,” he added. The records were obtained by the Ottawa Citizen using the Access to Information Act. Advertisement 4 Story continues below This advertisement has not loaded yet, but your article continues below. Article content The monument is expected to open Dec. 12. Photo by Tony Caldwell / Postmedia The Memorial to the Victims of Communism has already been the focus of multiple controversies over its exact purpose, location, size and cost over the last 15 years. The price tag for the project has ballooned to an estimated $7.5 million — including $6 million in public funds — from an original budget of $1.5 million. The memorial, originally started by the Conservative government of then-prime minister Stephen Harper, was supposed to be funded entirely through private donations. But taxpayers are now footing most of the bill as that private fundraising initiative fell far short when significant public financial support did not materialize. In addition, a Holocaust education organization has warned that a large number of names that were to be inscribed on the memorial had links to the Nazis. The Friends of Simon Wiesenthal Center has pointed to a report prepared for the Department of Canadian Heritage which recommended more than half of the 550 names planned to go on the memorial be removed. “What we want is a clear commitment from the minister that the names of those who helped the Nazis or were involved in the Holocaust not be honoured on this memorial,” Friends of Simon Wiesenthal Center official Jaime Kirzner-Roberts said in a Dec. 3 interview. “We feel this is a very reasonable request and it is concerning we cannot get a simple answer.” Advertisement 5 Story continues below This advertisement has not loaded yet, but your article continues below. Article content The department had already determined that 50 to 60 of the names or organizations that were to go on the memorial were likely directly linked to the Nazis, according to the documents. A number of the entries should be removed because they had no direct link to Canada, the report also noted. As originally planned, there were to be 553 entries on the memorial’s Wall of Remembrance. FROM THE ARCHIVES: A monumental controversy: History of the Memorial to Victims of Communism Charles Thibault-Béland, a spokesperson for Heritage Minister Pascale St-Onge, said Dec. 3 that at this point there will be no names on the memorial. Department officials are still reviewing the backgrounds of the names and events to be commemorated. Yvan Baker, the Liberal MP for Etobicoke Centre, will inaugurate the memorial , Canadian Heritage announced Dec. 10. Federal officials in other departments have also continued to warn Canadian Heritage that the inclusion of Nazi collaborators on the memorial will cause international embarrassment. “It is important to note that many anti-communist and anti-Soviet advocates and fighters were also active Nazi collaborators, who committed documented massacres,” Global Affairs Canada officials warned their counterparts at Canadian Heritage in 2021. Advertisement 6 Story continues below This advertisement has not loaded yet, but your article continues below. Article content Private donations had already been made to the monument in the names of Nazi collaborators, CBC News reported in July 2021. Those included Roman Shukhevych, a Ukrainian nationalist whose troops murdered Jews and Poles, and Ante Pavelić who ran a Nazi puppet regime in Croatia and is considered a chief perpetrator of the Holocaust in the Balkans, the CBC reported. David Pugliese is an award-winning journalist covering Canadian Forces and military issues in Canada. To support his work, including exclusive content for subscribers only, sign up here: ottawacitizen.com/subscribe Recommended from Editorial Victims of Communism memorial delayed over Nazi link controversy to open Feds won't commit to cutting alleged Nazi collaborators' names from Victims of Communism memorial Article content Share this article in your social network Share this Story : Feds ignored calls to rename Victims of Communism memorial Copy Link Email X Reddit Pinterest LinkedIn Tumblr Comments You must be logged in to join the discussion or read more comments. Create an Account Sign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. Trending Downtown Ottawa streets briefly closed for suspicious package News Canada Post strike threatens donations to Ottawa charities News Feds ignored calls to rename Victims of Communism memorial Defence Watch Canadian special forces spy plane unit sees staff exodus Defence Watch Police find missing 51-year-old man dead Local News Read Next Latest National Stories Featured Local SavingsBoots has up to 60% off items in massive sale with prices starting less than £1

Kanye West Reactivates His Twitter And Fans Don’t Know How To Feel About ItHyderabad, Dec 28 (PTI) The newly formed Hyderabad Disaster Response and Asset Protection Agency (HYDRAA) has reclaimed 200 acres of land, including eight parks, 12 lakes, and four government land parcels, the agency's Commissioner A V Ranganath said on Saturday. HYDRAA has successfully created awareness among citizens about the Full Tank Level (FTL) and 'buffer zones' of water bodies (areas where no construction should take place), he told reporters here. A HYDRAA police station will soon be established, he said. The agency will begin demarcating FTL in the new year and has identified 1,025 water bodies. Ranganath said steps would be taken in 2025 to carry out "geofencing" of parks and government lands using technology. Geofencing is a technology that allows the movements of a person, vehicle, etc., to be recorded or limited using satellite signals. HYDRAA condemned attempts by some to create a misconception that it is solely meant for demolishing unauthorised constructions, he said. The agency will also participate in rejuvenating lakes and is considering launching an FM channel to provide weather forecasts, the official said. HYDRAA will not act against residential houses built in the past, even if they are unauthorised, but illegal commercial constructions will continue to be treated as such, he added. The Telangana government established HYDRAA in 2024 to protect government assets, such as lakes, from encroachments and other illegal activities. However, the agency has faced intense criticism in recent months from the opposition, which alleges that it is demolishing poor people's houses and harming the real estate sector in the city. (This story has not been edited by THE WEEK and is auto-generated from PTI)